. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Parkinsonism Relat Disord. 2014 Dec 15;21(3):297–299. doi: 10.1016/j.parkreldis.2014.10.016

Table 2.

Association of the type of dopaminergic therapy taken at baseline on the sum of the ranks adjusting for covariates

	Full Model			Reduced Model

	Parameter Estimate	Standard Error	P-value	Parameter Estimate	Standard Error	P-value

Dopamine Agonist versus Levodopa	28.13	107.30	0.79	36.92	94.79	0.70
Dopamine Agonist versus Levodopa and Dopamine Agonist	243.70	133.61	0.07	260.29	112.14	0.02
Intercept	8538.76	339.22	<.0001	8349.49	261.46	<.0001

Full model is adjusted by age, education, taking medications that were felt to likely impair cognitive performance, amantadine, COMT-I (Tolcapone, Entacapone, Stalevo), MAO-I (Rasagiline, Selegiline), other Adjunctive (Co-Q10, Carbidopa alone), levodopa equivalent daily dose at baseline and body weight.

Reduced model is adjusted by age, education, taking cog-meds and amantadine.